Toggle Main Menu Toggle Search

Open Access padlockePrints

Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease

Lookup NU author(s): Dr Rachel CrosslandORCiD, Professor Anne Dickinson



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Copyright © 2022 Doglio, Crossland, Alho, Penack, Dickinson, Stary, Lacerda, Eissner and Inngjerdingen.Hematopoietic allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with hematological malignancies. However, due to disparities in major and minor histocompatibility antigens between donor and recipient, severe inflammatory complications can occur, among which chronic graft-versus-host disease (cGVHD) can be life-threatening. A classical therapeutic approach to the prevention and treatment of cGVHD has been broad immunosuppression, but more recently adjuvant immunotherapies have been tested. This review summarizes and discusses immunomodulatory approaches with T cells, including chimeric antigen receptor (CAR) and regulatory T cells, with natural killer (NK) cells and innate lymphoid cells (ILCs), and finally with mesenchymal stromal cells (MSC) and extracellular vesicles thereof. Clinical studies and pre-clinical research results are presented likewise.

Publication metadata

Author(s): Doglio M, Crossland RE, Alho AC, Penack O, Dickinson AM, Stary G, Lacerda JF, Eissner G, Inngjerdingen M

Publication type: Review

Publication status: Published

Journal: Frontiers in Immunology

Year: 2022

Volume: 13

Online publication date: 17/11/2022

Acceptance date: 31/10/2022

ISSN (electronic): 1664-3224

Publisher: Frontiers Media S.A.


DOI: 10.3389/fimmu.2022.1045168

PubMed id: 36466922